Invivyd WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced today the addition of Ajay Royan to its Board of Directors. Royan, a venture capitalist known for investing in ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million2024 year ...

(RTTNews) - Invivyd, Inc. (IVVD) announced Loss for full year that decreased from the same period last year but missed the Street estimates. The company's bottom line totaled -$169.93 million ...

Invivyd, Inc. reported a net product revenue of $13.8 million for Q4 2024 from its monoclonal antibody PEMGARDA™, marking a 48% increase from Q3 2024, with total revenue for 2024 reaching $25.4 ...

WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced today the addition of Ajay Royan to its Board of Directors. Royan, a venture capitalist known for investing in ...

70.36% of the stock is owned by hedge funds and other institutional investors. Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and ...